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Abstract
Background: Fluorescent tags, including small organic molecules and fluorescent proteins, enable the localization
of protein molecules in biomedical research experiments. However, the use of these labels may interfere with the
formation of larger-scale protein structures such as amyloid aggregates. Therefore, we investigate the effects of
some commonly used fluorescent tags on the morphologies of fibrils grown from the Alzheimer’s disease-
associated peptide Amyloid b 1-40 (Ab40) and the Parkinson’s disease-associated protein a-synuclein (aS).
Results: Using transmission electron microscopy (TEM), we verify that N-terminal labeling of Ab40 with AMCA,
TAMRA, and Hilyte-Fluor 488 tags does not prevent the formation of protofibrils and amyloid fibrils of various
widths. We also measure the two-photon action cross-section of Ab40 labelled with Hilyte Fluor 488 and
demonstrate that this tag is suitable for use with two-photon fluorescence techniques. Similarly, we find that Alexa
Fluor 488 labelling of aS variant proteins near either the N or C terminus (position 9 or 130) does not interfere
with the formation of amyloid and other types of aS fibrils. We also present TEM images of fibrils grown from aS
C-terminally labelled with enhanced green fluorescent protein (EGFP). Near neutral pH, two types of aS-EGFP fibrils
are observed via TEM, while denaturation of the EGFP tag leads to the formation of additional species.
Conclusions: We demonstrate that several small extrinsic fluorescent tags are compatible with studies of amyloid
protein aggregation. However, although fibrils can be grown from aS labelled with EGFP, the conformation of the
fluorescent protein tag affects the observed aggregate morphologies. Thus, our results should assist researchers
with label selection and optimization of solution conditions for aggregation studies involving fluorescence
techniques.
Background
Fluorescent tags are commonly used to monitor proteins
and peptides in microscopy and spectroscopy experi-
ments [1-3]. However, incorporation of these labels may
affect protein structure or block protein-ligand interac-
tions; therefore it is important to verify that specific tags
and labelling locations are suitable for a particular appli-
cation. In the context of amyloid aggregation studies, in
which proteins or peptides associate to form various oli-
gomeric structures, it is necessary to investigate poten-
tial perturbations of the aggregation reaction due to the
presence of the label. In particular, because multiple
fibril types may be grown from one protein or peptide
[4], it is essential to ensure that incorporation of a label
is compatible with multiple aggregation pathways.
In this Paper, we present TEM and other characteriza-
tions of fluorescently labelled Ab40 peptide and aS pro-
tein. Ab is associated with Alzheimer’s disease, while aS
is linked to Parkinson’s disease; therefore fluorescently
labelled aS/Ab constructs may be useful for understand-
ing the initiation and progression of these common
human neurodegenerative disorders. Indeed, fluores-
cently-labelled Ab and aS constructs have been used in
numerous studies of protein interactions, trafficking,
and degradation, as well as in investigations of structural
changes linked to amyloid aggregation (see articles refer-
enced in [5,6]). However, relatively few researchers have
examined the effects of these fluorescent tags on Ab/aS
aggregate morphologies [5,7-12].
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and atomic force microscopy, enable identification and
classification of aggregates, which may include protofi-
brils, amyloid fibrils containing varying numbers of
strands, and amorphous aggregates. In contrast, meth-
ods used to quantify fibril production, such as thiofla-
vin-T binding, light scattering, Fourier transform
infrared spectroscopy, and circular dichroism spectro-
scopy, cannot discriminate among different types of b-
sheet rich species [13,14]. Nevertheless, TEM imaging
provides no quantitative information about aggregation
kinetics or about the concentrations of the observed
fibrils. In addition, rare species or aggregates that do
not stick to the TEM grids may not be detected.
Therefore, TEM can confirm the presence of a particu-
lar type of aggregate, but it cannot prove that a type is
disallowed.
We examine Ab40, peptides tagged with three extrin-
sic fluorophores (AMCA, TAMRA, and Hilyte Fluor
488). These labels were selected because their emission
peaks are reasonably well-separated, making them
potentially useful for multi-channel imaging or fluores-
cence cross-correlation spectroscopy applications. In
addition, peptides tagged with these dyes are readily
available from commercial sources.
For aS, we compare small organic dye (Alexa Fluor
488) with fluorescent protein (EGFP) labelling. Alexa
Fluor 488, EGFP, and Hilyte Fluor 488 have similar
excitation and emission spectra, and therefore are
compatible with similar optical systems. In addition,
investigations of the effects of fluorescent protein tags
are particularly important given the high potential
value of these tags for in vivo and cell-based experi-
ments [11]. However, the large size of most fluorescent
proteins (~29 kDa) compared to aS (14.5 kDa), as well
as the potential environmental sensitivity of fluorescent
protein tags, raises questions regarding the suitability
of aS-fluorescent protein constructs for aggregation
studies [9,15].
Our TEM images show that several extrinsic fluores-
cent labels do not preclude the growth of multiple fibril
varieties for Ab40 and aS. In contrast, we observe two
distinct types of rigid aggregates when aS-EGFP solu-
tions are incubated near physiological pH. Moreover,
disruption of the EGFP tag results in the growth of
additional species. Therefore, although the fluorescent
protein label does not prevent aggregation of the aS-
EGFP construct, the fibrillization pathway is affected by
the conformation of the EGFP tag. We believe that our
images will provide a starting point to assist researchers
in fluorophore selection for aggregation studies,
although additional characterizations will be necessary
for some applications.
Figure 1 TEM images of aggregates grown from Ab40 labelled
with three extrinsic fluorescent dyes. Each column corresponds
to one fluorophore. The scale bar is 200 nm wide and all images
are shown at the same magnification. Unless otherwise noted, the
samples were incubated at 22°C under quiescent conditions. The
protein concentrations, incubation times t, and other solution
conditions are as follows: (A) 200 μM Hilyte Fluor 488-Ab40 in water,
t = 7 days. (B) 15 μM Hilyte Fluor 488-Ab40 in 100 mM pH 7
NaPhos buffer, t=8 weeks. (C) 10 μM Hilyte Fluor 488-Ab40 in 50
mM pH 6 NaPhos, t=4 weeks. (D) 10 μM Hilyte Fluor 488-Ab40 in
50 mM, pH 7 NaPhos with 5% TFE, t=10 weeks. (E) 25 μM TAMRA-
Ab40 incubated at 37°C with shaking in 50 mM pH 7 NaPhos with
10% TFE, t = 2 weeks. (F) 50 μM TAMRA-Ab40 in 100 mM pH 7
NaPhos, t=8 weeks. (G) 73 μM TAMRA-Ab40 in 50 mM pH 7
NaPhos, t = 15 weeks. (H) 50 μM TAMRA-Ab40 in 50 mM pH 6
NaPhos, t = 20 weeks. (I) 25 μM AMCA-Ab40 incubated at 37°C with
shaking in 50 mM pH 7 NaPhos containing 10% TFE, t = 2 weeks.
(J) 25 μM AMCA-Ab40, shaken overnight at 37°C, followed by
incubation at 22°C under quiescent conditions for 5 weeks. (K) 20
μM AMCA-Ab40 in 50 mM, pH 7 NaPhos with 100 mM NaCl, t =4
weeks. (L) 20 μM AMCA-Ab40 in 50 mM, pH 7 NaPhos, t = 4 weeks.
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Extrinsic Dye Labelled Ab40 Aggregates
F i g u r e1s h o w sc o l u m n so fT EM images of aggregates
grown from Hilyte Fluor 488-, TAMRA-, and AMCA-
Ab40. Various fibril types were apparent in these sam-
ples, including thin flexible “protofibrils” (Figure 1A,E-F,
I) and rigid fibrils of various widths (Figure 1B-D,1E-H,
J-L). Thus, labelling with these small organic fluoro-
phores does not prevent the formation of many types of
amyloid aggregates. In general, samples with higher con-
centrations of peptide and lower ionic strengths were
more likely to generate protofibrils. However, details of
the solution preparations caused variations in fibril
types and morphologies were not wholly reproducible.
For the TAMRA and Hilyte Fluor 488 labelled Ab40
samples shown in Figure 1, the solutions initially
appeared uniformly fluorescent when viewed by eye
(AMCA emits in the UV, and so the AMCA-Ab40 sam-
ples appear transparent). After incubation in aggregation-
promoting conditions, fluorescent clumps were apparent
in the bottom of these sample tubes, while the superna-
tants of these solutions became more transparent, sug-
gesting that the TAMRA and Hilyte Fluor 488 tags were
incorporated into the observed aggregates. Furthermore,
the labelling efficiencies were high for the synthetic Ab40
peptides we examined (see Methods), and similar images
were obtained for all three fluorophores; therefore the
observed fibrils likely contained tagged peptides.
Potential applications of fluorescently labelled peptides
include two-photon imaging and two-photon fluores-
cence correlation spectroscopy. The two-photon action
cross-sections of AMCA and TAMRA are sufficient for
these applications [16-18]. However, the cross-section
for Hilyte Fluor 488, which is an analogue of Alexa
Fluor 488 has not been previously determined, as far as
we know. Therefore, we measured the two-photon
action cross-section for Hilyte Fluor 488-Ab40, and
compared this curve to the free Alexa Fluor 488 dye
cross-section (Figure 2). We find that Hilyte Fluor 488
is a good two-photon probe when excited at ~760-850
nm and ~940-1000 nm, although its cross-section does
not coincide exactly with the Alexa Fluor 488 spectrum.
Alexa-488-aS Aggregates
When aggregates grown from aS variant proteins
labelled with Alexa Fluor 488 are imaged using TEM,
we detect both rigid fibrils (Figure 3A-G) and flexible
“TFE fibrils” (Figure 3F-L), which are similar to species
previously observed for unlabelled aSi ns o l u t i o n sc o n -
taining TFE or detergents [19,20]. The rigid fibrils are
most frequently narrow (~4-5 nm width) and straight,
but may also appear twisted and thicker, with widths
ranging from 10-20 nm. The “TFE fibrils” are typically
~10-13 nm wide. As was observed for the Ab40 pep-
tides, fluorescent aggregates grown from Alexa Fluor
488 labeled aS variant proteins were typically visible by
eye after incubation.
For human wild-type (WT) aS, N-terminal (position
9) and C terminal (position 130) labelling is compatible
with growth of both fibrils types (Figure 3A-B, 3H-J).
We also investigated fluorescent aggregates grown from
two Parkinson’s disease-associated aSv a r i a n t s ,A 3 0 P
and A53T aS. For A30P aS, both N terminal and C
terminal labels were examined (Figure 3C,E,F,G,K),
while for A53T, we examined only N terminal labelling
(Figure 3D). Although we don o ti n v e s t i g a t eaw i d e
range of solution conditions for the variants, we do
observe fluorescently labelled aggregates for both
mutants. Therefore, it is likely that both C terminal and
N terminal labels may be employed for multiple aS
variants.
Note that our images do not enable direct compari-
sons of aggregation properties of proteins labelled at the
C vs. N termini because of variability in solution condi-
tions and incubation times, as well as the possible pre-
s e n c eo fo l i g o m e r i cs p e c i e si nt h es t o c ks o l u t i o n s .
Therefore, we are only able to observe that certain
structures are not precluded by the label, but cannot
determine whether a label or labelling location may tend
to favour a particular type of aggregate. More detailed
studies are necessary to determine whether labelling has
any subtle effects on aggregation pathway selection.
EGFP-aS Aggregates
We observed fibrils when samples containing 75 μM
and 150 μM aS-EGFP in PBS were prepared using
Figure 2 Two-photon action cross-section of Hilyte Fluor 488
labelled Ab40. The two-photon action cross-section (jfs2p)o f
Hilyte Fluor 488 labelled Ab40 is compared to that for Alexa Fluor
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ever, we were unable to detect fibrils via TEM when
protein stocks were filtered (100 kDa cut-off) prior to
incubation when all other solution conditions, including
incubation time and protein concentration as measured
by UV absorbance at 488 nm, were held constant. Simi-
lar results were obtained for aS-EGFP in Tris buffer
with 100 mM NaCl; we observed fibrils in a 35 μM
unfiltered sample (Figure 4D), but were unable to find
fibrils in a sample prepared using a filtered protein
stock and identical solution conditions and protein con-
centration. Interestingly, the addition of a small amount
(~4 μMo u to f3 4μM total) of dialyzed, unfiltered pro-
tein to samples prepared using filtered protein resulted
in the formation of aS-EGFP fibrils (Figure 4E-G).
Although TEM imaging is not a quantitative technique,
these preliminary results suggest that “seeding” samples
with unfiltered or pre-aggregated material may promote
fibril formation. However, additional experiments must
be done to verify this result.
Additional images of aS-EGFP fibrils gown from
seeded or unfiltered solutions at pH ~7.5 in various buf-
fer conditions are shown in Figure 4H-J. The aS-EGFP
fibrils appear to have a thin, straight core (~5-7 nm in
diameter), around which winds a somewhat indistinct or
blurry helix. The total fibril diameter is ~22 nm, and the
helical period is variable, ranging from ~140 nm to over
300 nm. In some samples, shorter, untwisted, multi-
stranded rigid fibrils were also observed (Figure 4B,G).
When aS-EGFP solutions containing fibrils were
examined by eye, they appeared uniformly fluorescent,
unlike the extrinsic fluorophore-labelled aS samples in
which fluorescent aggregated material was clearly visible
at the bottom of the tubes. This may be a result of aS-
EGFP fibrils remaining suspended in solution, or the
fibril fraction may be a minor component of the sample.
Alternatively, the EGFP tag may be quenched or altered
in the aS-EGFP fibrils [11].
Fluorescent protein tertiary structure can be disrupted
by extremes of pH [21,22] or by the addition of moderate-
to-high concentrations of TFE [23]. Loss of native tertiary
structure results in loss of green fluorescence and a shift
in the absorbance peak [21]. In Figure 5, we show that the
spectral features of acid-denatured aS-EGFP are similar to
those of EGFP alone. In addition, fluorescence loss occurs
above ~10% TFE for both EGFP and aS-EGFP after incu-
bation for > 24 hours at 37°C (Figure 5B).
Figure 6 shows TEM images of aS-EGFP aggregates
grown at low pH and/or in the presence of TFE. In low
ionic strength, pH 2.4 solutions, rigid, amyloid-like
fibrils ~12 nm in diameter were observed (Figure 6A-B).
However, the inclusion of 150 mM NaCl in these
Figure 3 TEM images of aggregates grown from aSv a r i a n t s
labelled with Alexa Fluor 488. The scale bar is 200 nm wide and
all images are shown at the same magnification. All samples
contained 10 mM pH 7.5 NaPhos, and unless otherwise specified,
the solutions were incubated at 37°C with shaking. The protein
concentrations, incubation times t, and other solution conditions are
as follows: (A) 43 μM WT/E130C-Al488 aS with 150 mM NaCl, t=1
week. (B) 43 μM WT/S9C-Al488 aS with 150 mM NaCl and 5% TFE, t
= 1 week. (C) 50 μM A30P/E130C-Al488 aS with 150 mM NaCl, t=2
weeks. (D) 50 μM A53T/S9C-Al488 aS with 150 mM NaCl, t=2
weeks. (E) 50 μM A30P/E130C-Al488 aS with 150 mM NaCl and 5%
TFE, t=2 weeks. (F-G) 50 μM A30P/E130C-Al488 aS with 5% TFE, t
= 2 weeks. (H) 43 μM WT/S9C-Al488 aS with150 mM NaCl and 15%
TFE, incubated at 22°C under quiescent conditions, t = 5 weeks. (I)
50 μM WT/E130C-Al488 aS with 150 mM NaCl and 5% TFE,
incubated at 22°C under quiescent conditions, t = 2 weeks. (J) 50
μM WT/E130C-Al488 aS with 5% TFE, incubated at 22°C under
quiescent conditions, t = 1 week. (K) 50 μM A30P/S9C-Al488 aS
with 10% TFE, t = 2 weeks. (L) 50 μM A30P/E130C-Al488 aS, t =2
weeks.
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(Figure 6C). Moreover, pH 7.5 aS-EGFP solutions
appear clear or cloudy-white after incubation at for > 24
hours in the presence of 10-15% TFE. TEM examination
of such samples reveals a combination of amorphous
aggregates, thin, flexible, fibrillar aggregates, and rigid
fibrils that resemble classical amyloid (Figure 6D-E).
Prolonged room-temperature, pH 7.5 incubation of aS-
EGFP in the presence of 10-15% TFE resulted in the
formation of flexible aggregates (Figure 6F-H). When a
combination of acidic conditions and TFE were
employed, both short, disordered, fibrillar aggregates
and rigid fibrils were observed (Figure 6I-J).
Discussion
In this Paper, we have demonstrated that several small
extrinsic fluorescent tags are suitable for use in Ab40
Figure 5 Spectral properties of the aS-EGFP construct.( A )
Absorbance spectra of aS-EGFP (dashed lines) and EGFP (solid
lines). Spectra are shown for 5 μM protein in 10 mM phosphoric
acid (pH 2.4, red lines) and 10 mM NaPhos buffer (pH 7.5, black
lines). (B) The normalized fluorescence emission from aS-EGFP
(squares) and EGFP (circles) as a function of TFE concentration. The
signal from 0.3 μM protein is measured after a 2.0 ± 0.5 minute
incubation at 22°C (cyan symbols), after 2.0 ± 0.5 minutes at 37°C
(red symbols), and after 24 ± 2 hours at 37°C (yellow symbols). The
error bars reflect the standard deviations of measurements of three
identical samples and baseline uncertainties.
Figure 4 TEM images of aggregates grown from seeded or
unfiltered aS-EGFP stocks. The scale bar is 200 nm wide and all
images are shown at the same magnification. Unless otherwise
specified, all solutions contained PBS buffer (10 mM pH 7.5 NaPhos,
150 mM NaCl) and the samples were incubated with shaking at 37°C.
The protein concentrations, incubation times t, and other solution
conditions are as follows: (A-B) 75 μM unfiltered aS-EGFP, t = 3 weeks.
(C) 150 μM unfiltered aS-EGFP, t = 3 weeks. (D) 35 μMu n f i l t e r e daS-
EGFP in pH 7.4 Tris buffer with 100 mM NaCl, t = 3 weeks. (E-G) 30 μM
filtered aS-EGFP plus ~4 μM unfiltered aS-EGFP “seed” in pH 7.4 Tris
with 100 mM NaCl, t = 4 weeks. (H) 20 μMu n f i l t e r e daS-EGFP in pH
7.4 Tris with 100 mM NaCl, t = 4 weeks. (I-J) 150 μMf i l t e r e daS-EGFP
plus ~ 8 μM unfiltered aS-EGFP “seed”, t =4w e e k s .
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TAMRA and Hilyte Fluor 488 labels do not preclude
the formation of many types of amyloid and fibrillar
aggregates for Ab40 (Figure 1). These results are in
accordance with previous studies of Ab, which demon-
strated that extrinsic fluorophore labelling does not pre-
vent the formation of classic amyloid aggregates
[5,7,8,10]. In addition, the Alexa Fluor 488 tag does not
prevent the formation of classic amyloid fibrils and
“TFE protofibrils” [19] for WT aS labelled at position 9
or position 130, and it appears that this tag is also suita-
ble for studies of A30P and A53T aS (Figure 3).
In contrast, we find that EGFP labelling of aS favours
the formation of two types of rigid aggregates when pro-
tein solutions are incubated near physiological pH (Fig-
ure 4). However, we have only been able to observe
fibrils in samples that have been seeded with pre-aggre-
gated material. Moreover, it is not clear whether the aS-
EGFP fibrils retain their fluorescence; fluorescent
clumps formed in samples containing aS labelled with
Alexa Fluor 488, but no similar clumps were seen in the
aS-EGFP samples. Recently, van Ham, et al. observed a
reduction in fluorescence for fibrils formed from YFP
labelled aS, which they attribute to energy migration
Förster resonant energy transfer (also known as homo-
FRET), rather than disruption of the YFP tertiary struc-
ture [11]. It is possible that a similar effect occurs for
aS labelled with EGFP tag, but we cannot verify this
with our current data. Additional experiments are
necessary to determine whether the native EGFP fold
remains intact in the aS-EGFP fibrils.
Interestingly, we are able to grow fibrils from aS-
EGFP in solutions in which EGFP tertiary structure is
likely disrupted (Figure 6). Given the fact that denatured
fluorescent proteins are aggregation-prone [24,25], and
the observation that amyloid fibrillization may be a uni-
versal property of polypeptides [26], it is possible that
the properties of the EGFP tag, rather than the smaller
aS domain, dominate the fibrillization reaction under
these conditions. Therefore, care must be employed
when using the EGFP tag to study protein aggregation
in potentially denaturing conditions.
Conclusions
We have presented TEM images and other characteriza-
tion of aggregates composed of fluorescently labelled
proteins. Our images support the use of several small
intrinsic fluorescent tags in studies of aSa n dA b40
aggregation. In addition, we present images of fibrils
grown from aS labelled with EGFP. Near neutral pH,
aS-EGFP fibrils are rigid and often feature an indistinct
helix wound around a rigid core. Acid or TFE denatura-
tion of the EGFP tag resultsi nt h ef o r m a t i o no fa d d i -
tional types of aS-EGFP aggregates. Our images may
Figure 6 TEM images of aS-EGFP aggregates grown in
potentially denaturing conditions. The scale bar is 200 nm wide
and all images are shown at the same magnification. All samples
were incubated for three weeks, and unless otherwise specified, the
incubation temperatures were 37°C. The protein concentrations and
other solution conditions are as follows: (A-B) 50 μM aS-EGFP at pH
2.4. (C) 50 μM aS-EGFP at pH 2.4 with 150 mM NaCl. (D-E) 50 μM
aS-EGFP in pH 7.5 NaPhos with 15% TFE. (F) 50 μM aS-EGFP in pH
7.5 NaPhos with 10% TFE, after incubation at 22°C under quiescent
conditions. (G) Same as F, but the solution contained 75 μM aS-
EGFP. (H) Same as F, but the solution contained 15% TFE. (I) 50 μM
aS-EGFP at pH 2.4 with 15% TFE. (J) 50 μM aS-EGFP at pH 2.4 with
15% TFE and 150 mM NaCl.
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mization of experimental conditions for protein aggrega-
tion studies involving fluorescence techniques.
Methods
Solutions and Reagents
MilliQ or HPLC grade water was used to prepare all
solutions. Sodium phosphate (NaPhos) buffer salts were
purchased from Sigma. Trizma brand pre-set pH 7.7
crystals (Sigma) were used to prepare Tris buffers that
were pH ~7.4 at 37°C. Temperature-dependent changes
in the pH of other buffer solutions were ignored. Acros
Organics brand 99.8% pure TFE was purchased from
Fisher Scientific. Sodium azide (Sigma) at ~0.02% w/v
was added to all solutions incubated at ~20°C for over
24 hours. A bench-top orbital shaker operating at 200
RPM was used to agitate some samples during
incubation.
Ab40 Solubilization
The three Ab40 peptide tags discussed here are Hilyte
Fluor 488, TAMRA (5-carboxytetramethylrhodamine),
and AMCA (7-Amino-4-methylcoumarin-3-acetic acid).
N-terminally fluorophore labelled, synthetic Ab40 pep-
tides were purchased from Anaspec. The percentage of
singly-labelled Ab40 peptide was measured by the man-
ufacturer using HPLC and mass spectrometry, and was
reported as > 90% for all batches examined in this
Paper.
Protein stock solution preparation roughly followed
the protocol in Bitan and Teplow [27]. Briefly, the lyo-
philized peptides were dissolved at ~1 mg/mL in 2 mM
NaOH, and then these solutions were flash-frozen in
liquid nitrogen and relyophilized. Final solubilization
was accomplished by dissolving the powder into 10
mM, pH 10 carbonate buffer and filtering through YM-
30 or YM-50 Microcon filters (Millipore). An exception
to this procedure is shown in Figure 1A; for this sample,
0.1 mg of Hilyte Fluor 488 labelled Ab40 was dissolved
directly into water.
Alexa Fluor 488 Labelled aS Preparation
Alexa Fluor 488 was purchased from Invitrogen, and
labelling was generously performed by Trudy Ramlall
and Prof. David Eliezer of Weill Cornell Medical College
using previously described procedures [28]. However,
serine-to-cysteine mutations and labelling at position 9
w e r ep e r f o r m e do nA 3 0 Pa n dA 5 3 T ,i na d d i t i o nt oW T
aS. Furthermore, C-terminal labelling of WT and A30P
aS was also investigated via a glutamate-to-cysteine
mutation at position 130. Free dye was removed from
the samples by dialysis vs. 10 mM pH 7.5 NaPhos buffer
using Slide-A-Lyzer 10,000 MW cut-off dialysis cassettes
(Thermo-Fisher Scientific).
We estimated the dye-to protein ratio (F/P)o fo u r
dialyzed protein stocks using UV and visible light absor-
bance measurements via a double-beam Cary-300 spec-
trophotometer (Varian). All measurements were
obtained using a 1 cm path length, and the F/P ratio
was then calculated using [29]:
(F/P)=AMaxε280
P /[εMax
F (A280 − CL · AMax)] (1)
where A
Max is the measured peak absorbance, A
280 is
the measured absorbance at 280 nm, εMax
F is the dye’s
molar extinction coefficient at the peak, ε280
P is the
molar extinction coefficient for unlabeled protein at 280
nm, and CL is a correction factor that accounts for the
contribution of the fluorophore to the absorbance at
280 nm. We used ε280
P =5 ,1 2 0M-1cm -1 for aS [30],
while the values of CL and εMax
F f o rA l e x aF l u o r4 8 8
(0.11 and 72,000 M
-1cm
-1, respectively) were provided
by Invitrogen.
Using equation 1, we obtained F/P estimates ranging
from 0.9 to 2.1 for our aS stock solutions (the mean
v a l u ef o rt h en i n es t o c ks o l u t i o n sw ep r e p a r e dw a s1 . 4 ,
and the standard deviation was 0.4). Because aSc o n -
tains no cysteine residues, excepting the one introduced
for labelling purposes, the maximum F/P ratio should
be 1 after dialysis. However, the fluorescence properties
of Alexa Fluor 488 are sensitive to solution conditions
and to details of the target protein sequence [31], and
s ot h ee s t i m a t ep r o v i d e db yE q u a t i o n1i ss o m e w h a t
uncertain. Therefore, our F/P values suggest that the
labelling efficiency is reasonably good, but we cannot
report a precise degree of labelling.
aS-EGFP Expression
Vectors for mammalian expression of the human WT
aS-EGFP construct were a kind gift from Prof. Bradley
Hyman of Massachusetts General Hospital Medical
School at Harvard University; information about this
construct can be found in McLean, et al. [15]. Transfor-
mation into a bacterial vector and subsequent protein
expression was performed by Dr. Cynthia Kinsland and
the Cornell University Life Sciences Core Laboratories
Center Protein Production Facility.
Plasmid DNA was purified with the Qiagen Miniprep
kit. E. coli s t r a i nM a c h I( I n v i t r o g e n )w a su s e da sar e c i -
pient for transformations during plasmid construction
and for plasmid propagation and storage. PCR was per-
formed with Phusion DNA polymerase (New England
Biolabs) per the manufacturer’s instructions. DNA oligo-
nucleotides were ordered from IDT DNA. Site-directed
mutagenesis was performed by a standard PCR protocol
using PfuTurbo DNA polymerase per the manufacturer’s
instructions (Agilent) and DpnI (New England Biolabs)
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transformation.
Site-directed mutagenesis was performed on the pro-
vided plasmid to introduce a 6xHisTag at the C-termi-
nus of the aS-EGFP fusion protein. The primers used
for mutagenesis were: 5’-GGC ATG GAC GAG CTG
TAC AAG CAC CAT CAC CAC CAT CAC-3’ and 5’-
CTA GAG TCG CGG CCG CTT TAG TGA TGG
TGG TGA TGG TGC TT-3’. After transformation,
colonies were screened for the presence of the HisTag
by PCR using the following primer pair: 5’-GGG ATC
CAT CGC CAC CAT GG-3’ and 5’-CGC GGC CGC
TTT AGT GAT GG-3’. A plasmid which screened cor-
rectly was verified by sequencing. The final construct
was based on the cloning vector EGFP-N3, with aS
fused to the N-terminus of EGFP and a 6xHisTag fused
to the C-terminus of EGFP.
The fusion construct described above was moved into
a vector for E. coli expression by using the following pri-
mer pair: 5’-GGG TAG CAT ATG GAT GTA TTC
ATG AAA GGA CTT TC-3’ and 5’-CCC TAC TCG
AGT TAG TGA TGG TGG TGA TGG TGC-3’.F o l -
lowing amplification, the PCR product was digested
with NdeI and XhoI and ligated into a similarly digested
pTHT vector, resulting in an additional 6xHisTag added
to the N-terminus of the total fusion construct. pTHT
is a homemade vector which is equivalent to pET-28
(Novagen) with a TEV protease recognition site in place
of the thrombin recognition site.
Plasmids were transformed into BL21Star (DE3) cells
(Stratagene) harbouring the pRARE2 plasmid (Novagen)
and selected on kanamycin/chloramphenicol media at
a l ls t a g e s .P r o t e i ne x p r e s s i o ni ns h a k ef l a s k sw a sp e r -
formed as described in the pET-system manual, with
induction by IPTG (1 mM) at reduced temperature (15°
C) and overnight incubation post-induction. Cells were
harvested by centrifugation, lysed by sonication, and
HisTagged protein was purified on 5 mL HisTrap HP
columns (GE) using an AKTA FPLC. Buffers used for
purification were A) Binding: 20 mM Tris, pH 8.0, 500
mM NaCl, 30 mM Imidazole. B) Elution: 20 mM Tris,
pH 8.0, 500 mM NaCl, 500 mM imidazole. The column
was washed with A until the A
280 had returned to base-
l i n ea n dw a st h e nw a s h e dw i t h1 0 %Bi nAa n d1 5 %B
in A. For both washes, the wash was continued until the
baseline had stabilized (several column volumes). The
protein was then eluted in 100% B.
aS-EGFP Dialysis and Buffer Exchange
To prepare the samples shown in Figure 4, which were
buffered with Tris containing 100 mM NaCl or PBS (10
mM pH 7.5 NaPhos with 150 mM NaCl), the eluted
protein was dialyzed into the buffer using 10,000
MWCO Slide-A-Lyzer cassettes (Pierce). When dialyzed
into PBS, the protein partially precipitated, and visible
white material was removed from these solutions by
centrifugation for 30 minutes at 13,000 × g. The pellet
was collected and used to “seed” some samples (e.g. Fig-
ure 4I-J). Some aliquots of the dialyzed protein solutions
were spin-filtered using YM-100 Microcon filters (Milli-
pore) in order to obtain mostly monomeric stock solu-
tions. When necessary, filtered solutions were
concentrated using Amicon YM-10 filters (Millipore).
For the samples shown in Figure 6, filtering was per-
formed using a 0.22 μm syringe filter (Millex-GV, Milli-
pore), followed by filtering with YM-100 Microcon
filters (Millipore). Buffer exchange into water was per-
formed using Amicon YM-10 filters (Millipore), and the
aS-EGFP stocks were diluted into buffer or acid prior to
incubation.
Fluorescence Spectroscopy
Fluorescence emission spectra for 480-580 nm were col-
lected using 460 nm excitation via a QuantaMaster
fluorescence spectrofluorometer (Photon Technology
International). All fluorescence emission signals were
normalized to the emission signal from EGFP in PBS
(10 mM NaPhos, 150 mM NaCl) at room temperature
(22 ± 3°C). Correction for lamp fluctuations was auto-
mated by the vendor-supplied software. For the 37°C
samples, the temperature was maintained during fluor-
escence measurements using a NesLab Endocal RTE-
110 chiller/circulator (Thermo Scientific). In each case,
three identical samples were measured and their stan-
dard deviations calculated in order to determine the
measurement variability.
Determination of Protein Concentrations
UV or visible light absorbance measurements via a dou-
ble-beam Cary-300 spectrophotometer (Varian) were
used to quantify the amount of protein in the stock
solutions. The absorbance of the fluorophore was mea-
sured and concentration calculations were performed
using manufacturer-supplied extinction coefficients for
the organic dyes and ε =5 5 , 0 0 0M
-1 cm
-1 for EGFP
[32]. The fluorophore and protein concentrations were
assumed to be the same as in all cases.
Transmission Electron Microscopy Imaging
The general procedure for the TEM sample preparation
and imaging is described in Anderson, et al. [19]. Slight
variations of these techniques were employed to obtain
some of the images, including the occasional use of
homemade butvar grids (both carbon-coated and
uncoated butvar grids were employed), and the rare use
of 1% (w/v) uranyl acetate, rather than 2% (w/v) phos-
photungstic acid, stain. These differences in methodol-
ogy did not significantly affect the imaging results.
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A pulsed titanium sapphire Mai Tai laser (Spectra Phy-
sics) was used to excite the fluorophores over the wave-
length range of 760-1000 nm. The excitation and
emission light was focused through a 63x, 1.2 NA water
immersion C-Apochromat objective lens (Zeiss) into
~100 nM samples, which were mounted on an inverted
microscope (IX71, Olympus). The intensity of the exci-
tation beam was measured using a photodiode, while
the intensity of the emitted fluorescence was detected
using a gallium arsenide phosphide photomultiplier tube
(Hamamatsu). Linear fitting to the emitted light vs. inci-
dent intensity squared curves was performed at each
measured wavelength and the resultant slopes were nor-
malized to the values for a pH 11 Fluorescein standard
[33] in order to determine the two-photon action cross-
section for the unknown fluorophores.
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